Cigna Corp

Cigna and other health insurance providers reported strong second-quarter results, with the group beating revenue consensus by 2.8% while next quarter's guidance came in 1.7% below expectations. Cigna posted revenues of $71.56 billion, up 6.6% year over year and 1.2% above estimates, but its stock fell 4.8% since reporting to $282.28. CVS Health was the best performer with revenues of $106.1 billion, up 7.3% and 6.7% above expectations, yet its shares dropped 7% to $97.16. Progyny delivered the weakest guidance update, with revenues of $350.5 million up 5.3% but missing next quarter EBITDA guidance significantly, sending its stock down 13% to $26.29. Clover Health beat expectations with revenues of $743.2 million, up 55.6%, and its stock rose 10.6% to $4.58, while Molina Healthcare reported revenues of $10.87 billion, down 4.8% and in line with estimates, with its stock down 4.1% to $212.75.

Senator Elizabeth Warren is pushing bipartisan legislation to force the breakup of vertically integrated healthcare giants like UnitedHealth Group and CVS Health, arguing their control over insurance, pharmacies, and providers drives up patient costs. The Patients Before Monopolies Act, reintroduced in May with Senator Josh Hawley, would ban common ownership of insurers and pharmacies and require divestiture within one year. Warren highlighted how UnitedHealth’s UnitedHealthcare and Optum units link insurance to pharmacy services, and said the same consolidation applies to CVS Health. The bill targets the three major pharmacy benefit managers—UnitedHealth, CVS Health, and Cigna—which supporters say control every link in the prescription drug delivery chain.

Jefferies downgraded Cigna to Hold from Buy, cutting its price target to $307 from $336, citing a growing list of earnings headwinds and limited catalysts that outweigh the stock's discounted valuation. The brokerage lowered its 2027 earnings estimate to $32.77 per share, about 1% below consensus, arguing that expectations remain too optimistic given uncertainty around the strategic review of EviCore and the health insurance exchange business, increasing pressure from reduced GLP-1 drug coverage, and mounting regulatory scrutiny of pharmacy benefit managers. Jefferies estimates that a potential sale or wind-down of EviCore and the HIX business could create a meaningful earnings gap, with EviCore contributing $700 million to $1 billion in adjusted operating income, or $2.20 to $3.10 per share, and warned that share buybacks would not fully offset the dilution. The firm also expects weight-loss GLP-1 drug headwinds to intensify, projecting a 2027 earnings impact of about $126 million after management disclosed a $20 million-per-quarter headwind beginning in the second half of 2026, while highlighting risks from declining membership at key pharmacy benefit clients and state-level legislation targeting PBM pricing and transparency. Jefferies acknowledged the stock trades at roughly 8.3 times consensus 2027 earnings but said the discount is warranted given weaker growth prospects, limited catalysts for multiple expansion, and ongoing execution risks as the company transitions to a rebate-free PBM model.

Health insurance providers tracked by StockStory reported a strong first quarter, with aggregate revenues beating analyst consensus estimates by 1.4% and next-quarter revenue guidance in line. CVS Health was the standout, reporting revenues of $100.4 billion, up 6.2% year on year and exceeding expectations by 6.3%, while also beating full-year EPS guidance estimates. Cigna posted revenues of $68.52 billion, up 4.7% and beating estimates by 3%, but its stock fell 3.8% as investor expectations ran higher than published projections. Cencora was the weakest performer, with revenues of $78.36 billion missing estimates by 3.9%, sending its shares down 8.1%. Oscar Health saw revenues jump 52.6% to $4.65 billion, though that still came in 5.7% below expectations, while Centene topped estimates by 6.2% with revenues of $49.94 billion, up 7.1%, and lost 1.36 million customers to end the quarter with 26.27 million. On average, share prices across the 12-stock group have risen 31.4% since the latest earnings results.

UBS analysts say hospitals could build a more durable competitive advantage from artificial intelligence than health insurers, even as AI becomes a core operating layer across healthcare. Analyst A.J. Rice notes that while managed-care companies like UnitedHealth Group, Elevance Health, Humana, Cigna, and Centene are deploying AI for claims processing, prior authorization, and customer service, those efficiency gains are highly replicable and likely to be competed away through pricing or benefit enhancements. In contrast, large for-profit hospital operators such as HCA Healthcare, Tenet Healthcare, and Universal Health Services are using AI for revenue cycle management, denial appeals, and staffing optimization, and may maintain a multiyear lead over slower-moving nonprofit systems. UBS highlights that Universal Health Services generated approximately $50 million in annualized additional revenue from an AI coding platform, while HCA is using AI to fight claim denials and optimize nurse staffing with a Palantir-built platform. The report concludes that AI will improve profitability unevenly, with hospitals better positioned to retain gains and expand margins over time.

Novo Nordisk's oral Wegovy accounted for roughly one-third of all Wegovy prescriptions by May, according to a Bank of America report. For the week ending June 5, 2026, total weekly prescriptions for the oral treatment reached 159,000, and it made up 40% of all new Wegovy prescriptions during that week. The broader GLP-1 market saw total weekly prescriptions rise approximately 33% year-over-year in May, with monthly sales up 35% in April. Cigna will discontinue coverage of GLP-1 weight-loss treatments for its employee health plan starting July 1, 2026, while only 34% of employers cover the drugs for obesity management, according to a Pharmaceutical Strategies Group survey.